Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
C4 Therapeutics, Inc. - Common Stock
(NQ:
CCCC
)
6.430
-0.500 (-7.22%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,090,561
Open
6.810
Bid (Size)
6.360 (18)
Ask (Size)
6.450 (7)
Prev. Close
6.930
Today's Range
6.270 - 6.940
52wk Range
1.060 - 11.88
Shares Outstanding
48,797,226
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presentation
August 14, 2024
Investor Webcast Moved to Friday, September 13, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
CCCC Stock Earnings: C4 Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 01, 2024
CCCC stock results show that C4 Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Performance
YTD
-1.38%
-1.38%
1 Month
-1.68%
-1.68%
3 Month
+19.96%
+19.96%
6 Month
-34.05%
-34.05%
1 Year
+104.13%
+104.13%
More News
Read More
C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 01, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
July 16, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Key Takeaways From C4 Therapeutics Analyst Ratings
May 09, 2024
Via
Benzinga
C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day
July 08, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors
June 10, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
CCCC Stock Earnings: C4 Therapeutics Misses EPS, Misses Revenue for Q1 2024
May 08, 2024
Via
InvestorPlace
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 08, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Breaking Down C4 Therapeutics: 4 Analysts Share Their Views
February 26, 2024
Via
Benzinga
Analyst Expectations For C4 Therapeutics's Future
January 29, 2024
Via
Benzinga
C4 Therapeutics Inc. (NASDAQ: CCCC) Leading the Way in Wednesday Trading Based on Percentage Gain
January 10, 2024
Via
Investor Brand Network
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 29, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
April 09, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
April 08, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
March 05, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
March 04, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
February 22, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
Capital One Financial To Acquire Discover, Joins SSR Mining And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
February 20, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
7 Exciting Stocks Poised for Explosive Growth in Key Sectors
January 22, 2024
Via
InvestorPlace
C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines
January 09, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals
January 04, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
C4 Therapeutics, Inc.
Via
GlobeNewswire
MarketBeat Week in Review – 12/18 - 12/22
December 23, 2023
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
C4 Therapeutics blasts off: what's next?
December 18, 2023
Via
MarketBeat
Topics
ETFs
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.